Claims for Patent: 10,159,683

Summary for Patent: 10,159,683

Title:	Use of sustained release dexamethasone in post-cataract surgery inflammation
Abstract:	The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery.
Inventor(s):	Wong; Vernon G. (Menlo Park, CA), White; William S. (Birmingham, AL), Hu; Mae W. (Los Altos Hills, CA), Huang; Glenn T. (Fremont, CA), Karasina; Faina (Mountain View, CA)
Assignee:	ICON BIOSCIENCE, INC. (Watertown, MA)
Application Number:	16/018,931
Patent Claims:	1. A kit for the treatment of inflammation in the eye comprising: a vial containing a formulation consisting essentially of dexamethasone and triethyl acetyl citrate, wherein the w/w ratio of the dexamethasone:triethyl acetyl citrate is selected from the group consisting of about 6:94, about 9:91, and about 12:88; an injection syringe; a needle; a cannula; a dose loading guide; and a dose delivery guide. 2. The kit of claim 1, wherein the dose loading guide is designed to load a dose of about 4 .mu.L to about 6 .mu.L. 3. The kit of claim 2, wherein the dose loading guide is designed to load a dose of about 5 uL. 4. The kit of claim 1, wherein the concentration of the dexamethasone is about 9% w/w and the concentration of the triethyl acetyl citrate is about 91% w/w. 5. The kit of claim 4, wherein the dose loading guide is designed to load a dose of about 5 uL. 6. The kit of claim 1, further comprising instructions for administration of a single unit dose of about 5 .mu.L of the formulation into the anterior chamber of the eye following cataract surgery. 7. A unit dosage form consisting essentially of about 4 .mu.L to about 6 .mu.L of a composition consisting essentially of about 9% (w/w) dexamethasone and about 91% (w/w) triethyl acetyl citrate. 8. The unit dosage form of claim 7, wherein the volume of the composition is about 5 .mu.L. 9. The unit dosage form of claim 7, wherein the dose of the dexamethasone in the pharmaceutical composition is about 342 .mu.g to about 697 .mu.g. 10. The unit dosage form of claim 7, wherein the dose of dexamethasone in the composition is about 517 .mu.g. 11. A unit dosage form comprising an injection syringe containing about 4 .mu.L to about 6 .mu.L of a composition consisting essentially of about 9% (w/w) dexamethasone and about 91% (w/w) triethyl acetyl citrate. 12. The unit dosage form of claim 11, wherein the volume of the composition is about 5 .mu.L. 13. The unit dosage form of claim 11, wherein the dose of the dexamethasone in the pharmaceutical composition is about 342 .mu.g to about 697 .mu.g. 14. The unit dosage form of claim 11, wherein the dose of dexamethasone in the composition is about 517 .mu.g.